Development of In Vitro Assays for Advancing Radioimmunotherapy against Brain Tumors

Glioblastoma (GBM) is the most common primary brain tumor. Due to high resistance to treatment, local invasion, and a high risk of recurrence, GBM patient prognoses are often dismal, with median survival around 15 months. The current standard of care is threefold: surgery, radiation therapy, and che...

Descripción completa

Detalles Bibliográficos
Autores principales: Walter, Yohan, Hubbard, Anne, Benoit, Allie, Jank, Erika, Salas, Olivia, Jordan, Destiny, Ekpenyong, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394411/
https://www.ncbi.nlm.nih.gov/pubmed/35892697
http://dx.doi.org/10.3390/biomedicines10081796

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394411/
https://www.ncbi.nlm.nih.gov/pubmed/35892697
http://dx.doi.org/10.3390/biomedicines10081796

Ejemplares similares